XENETIC BIOSCIENCES, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
XENETIC BIOSCIENCES, INC. (XBIO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2022-11-09
- 2022-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2021-06-30 | $7.96K 10-Q · filed 2022-08-11 |
| 2021-03-31 | $17.57K 10-Q · filed 2022-05-12 |
| 2020-12-31 | $27.04K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |